At #SABCS 2024, check out the late-breaking oral presentation of Phase 3 data for our CDK4/6i in combination with standard-of-care therapy in HR+/HER2+ metastatic #BreastCancer. View the presentation here: https://t.co/ngcld7pWGm
BREAKING: The @US_FDA has approved our combination therapy for the treatment of metastatic castration-resistant #ProstateCancer (mCRPC) in adults with homologous recombination repair (HRR) gene mutations: https://t.co/81FqSALavM
A must read that I believe the future can be different!! #AACI AACI’s recent report on lack of diversity in US’s cancer center’s senior leadership https://t.co/Ncv3PlgeAW.
Never thought I would write a book, but our path to creating a breakthrough COVID-19 vaccine became an important chapter in human history, and I felt compelled to share our story.
Moonshot comes out on March 8: https://t.co/EZa3EFJ2OZ
We’re proud to announce that Pfizer & Merck KGaA Darmstadt, Germany, are providing a grant opportunity for HCP or patient focused independent education initiatives around immuno-oncology treatment in #UrothelialCarcinoma. Learn more: https://t.co/QskoE8yhjs
#PfizerProud to see steps being taken to recognize & address health disparities in #cancercare in underserved communities. Read about the barriers to accessing cancer care & how the healthcare community can work together to eliminate them. #PFEColleague https://t.co/YtBKJ4o0w1
What a remarkable honor from @CNN as we approach the end of a busy, challenging and successful year for @Pfizer. One I will never forget. My thanks to all our purpose-driven colleagues. They‘re the reason I have enjoyed every minute of my 28 years here. https://t.co/W4XLuHspcG
As a proud partner, @Pfizer applauds this step by #COVAX and congratulates @TedChaiban on this appointment. Addressing country readiness to ensure that vaccinations are available for people everywhere requires coordination and close collaboration across all stakeholders.
New ESMO urothelial cancer guidelines out. In M1 disease platinum based chemo and maintenance Avelumab is the preferred 1st line therapy [1A] . Then Enfortumab Vedotin as 2nd line [1A]. Erdafitinib is an option in FGFR patients [3b]. @myESMO https://t.co/S7ohTorjxP